The Insides News- The Insides Neo - fistuloclysis, distal feeding, best, alternative to parenteral nutrition, fistula, ostomy, ileostomy, chyme, enteral, oral nutrition, enteromate, intestinal failure, colon cancer, bowel cancer, gut cancer, ostomy appliance, high output, chyme, dehydration, defunctioned, ileus, lars, microbiome, lower interior resection syndrome, incontinent, incontinence, gut health, reversal surgery
Home
>
News
>
The Insides Company and Tutku Saglik Gerecleri Sign Distribution Agreement to introduce Chyme Reinfusion Therapy in Türkiye

The Insides Company and Tutku Saglik Gerecleri Sign Distribution Agreement to introduce Chyme Reinfusion Therapy in Türkiye

May 16, 2025

Source:The Insides Company Limited

On:16th May 2025

Organisation:The Insides Company Limited, Tutku Saglik Gerecleri

The Insides Company, a leading provider of novel chyme reinfusion therapy (CRT) medical devices for the treatment of intestinal failure, today announced Tutku Saglik Gerecleri as exclusive distributor of its products in Türkiye following the signing of a distribution agreement.

Garth Sutherland, CEO of The Insides Company, commented:“The Insides Company is pleased to launch with Tutku Saglik Gerecleri in Türkiye. After a comprehensive and competitive selection process, Tutku were selected as exclusive partner. Their portfolio and established relationships within the surgical community make them an excellent match for The Insides Company as we expand into this important market.”

Tuncay Sari, Managing Partner at Tutku, added:“We are proud to bring this innovative technology to Türkiye, where we've already seen clear interest and a recognized need among healthcare professionals. We look forward to working closely with The Insides Company to support the adoption of this solution and improve patient outcomes across the country.”

Type II intestinal failure is the inability of the gut to absorb enough nutrients, electrolytes, and fluids to sustain life without intravenous support. It can result from conditions like malabsorption, short bowel syndrome, fistulae, dysmotility, or obstruction. After colorectal surgery, patients often have an enterostomy to divert intestinal contents (chyme) during healing. This is typically left open for 6 to12 months, during which the discarded chyme can lead to intestinal failure and complications.

The Insides System is a medical device designed for chyme reinfusion therapy, a technique used to manage high-output enterocutaneous fistulas and enterostomies by returning the chyme to the patient’s digestive tract.

About Tutku Saglik Gerecleri

Tutku has been offering innovative solutions to the Turkish medical sector since 1993, through the principle of providing quality and reliable service by bringing together world-renowned brands with health professionals. The company, which acts with the principle of "Patient First", is among the leading companies in the sector in the supply and import of medical devices, surgical instruments and operating room consumables.

About The Insides Company

The Insides Company is a provider of life-saving medical devices that are purpose-designed to perform chyme reinfusion therapy for the treatment of patients with severe intestinal failure. The Insides Company’s vision is ‘a world that refeeds’.

Contacts

Tutku Saglik Gerecleri

Tuncay Sari, Managing Partner

Phone:+905333714261

Email:info@tutkusaglik.com

www.tutkusaglik.com

The Insides Company Limited

Garth Sutherland, CEO

Phone:+64 9 887 9309

Email:sales@theinside.co

Choose Your Language

Selecting language below will change the language for theinsides.co